Literature DB >> 27664883

Global microRNA profiling for diagnostic appraisal of melanocytic Spitz tumors.

Nicholas Latchana1, Kelly Regan2, J Harrison Howard1, Jennifer H Aldrink3, Mark A Ranalli4, Sara B Peters5, Xiaoli Zhang6, Alejandro Gru7, Philip R O Payne2, Lorena P Suarez-Kelly8, William E Carson1,8.   

Abstract

BACKGROUND: Melanoma skin cancer remains the leading cause of skin cancer-related deaths. Spitz lesions represent a subset of melanocytic skin lesions characterized by epithelioid or spindled melanocytes organized in nests. These lesions occupy a spectrum ranging from benign Spitz and atypical Spitz lesions all the way to malignant Spitz tumors. Appropriate management is reliant on accurate diagnostic classification, yet this effort remains challenging using current light microscopic techniques. The discovery of novel biomarkers such as microRNAs (miR) may ultimately be a useful diagnostic adjunct for the evaluation of Spitz lesions. miR expression profiles have been suggested for non-Spitz melanomas but have yet to be ascribed to Spitz lesions. We hypothesized that distinct miR expression profiles would be associated with different lesions along the Spitz spectrum.
MATERIALS AND METHODS: RNAs extracted from paraffin-embedded, formalin-fixed tissues of 11 resected skin lesions including benign nevi (n = 2), benign Spitz lesions (n = 3), atypical Spitz lesions (n = 3), and malignant Spitz tumors (n = 3) were analyzed by the NanoString platform for simultaneous evaluation of over 800 miRs in each patient sample.
RESULTS: Benign Spitz lesions had increased expression of miR-21-5p and miR-363-3p compared with those of benign nevi. Malignant Spitz lesions exhibited overexpression of miR-21-5p, miR-155-5p, and miR-1283 relative to both benign nevi and benign Spitz tumors. Notably, atypical Spitz tumors had increased expression of miR-451a and decreased expression of miR-155-5p expression relative to malignant Spitz lesions. Conversely, atypical Spitz lesions had increased expression of miR-21-5p, miR-34a-5p, miR-451a, miR-1283, and miR-1260a relative to benign Spitz tumors.
CONCLUSIONS: Overall, distinct miR profiles are suggested among Spitz lesions of varying malignant potential with some similarities to non-Spitz melanoma tumors. This work demonstrates the feasibility of this analytic method and forms the basis for further validation studies.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Melanoma; MicroRNA; Spitz

Mesh:

Substances:

Year:  2016        PMID: 27664883      PMCID: PMC5117820          DOI: 10.1016/j.jss.2016.06.085

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  42 in total

1.  MicroRNA expression signatures of stage, grade, and progression in clear cell RCC.

Authors:  Banumathy Gowrishankar; Ilsiya Ibragimova; Yan Zhou; Michael J Slifker; Karthik Devarajan; Tahseen Al-Saleem; Robert G Uzzo; Paul Cairns
Journal:  Cancer Biol Ther       Date:  2013-12-18       Impact factor: 4.742

Review 2.  Circulating microRNAs as diagnostic and prognostic tools for hepatocellular carcinoma.

Authors:  Yu-Cheng Zhang; Zhuo Xu; Tian-Fu Zhang; Ya-Li Wang
Journal:  World J Gastroenterol       Date:  2015-09-14       Impact factor: 5.742

3.  microRNA-21 is upregulated in malignant melanoma and influences apoptosis of melanocytic cells.

Authors:  Imke Satzger; Anika Mattern; Uta Kuettler; Dirk Weinspach; Margarete Niebuhr; Alexander Kapp; Ralf Gutzmer
Journal:  Exp Dermatol       Date:  2012-07       Impact factor: 3.960

4.  Differential expression of microRNA species in human gastric cancer versus non-tumorous tissues.

Authors:  Junming Guo; Ying Miao; Bingxiu Xiao; Rong Huan; Zhen Jiang; Dan Meng; Yanjun Wang
Journal:  J Gastroenterol Hepatol       Date:  2008-11-03       Impact factor: 4.029

5.  The atypical Spitz tumor of uncertain biologic potential: a series of 67 patients from a single institution.

Authors:  Mathew W Ludgate; Douglas R Fullen; Julia Lee; Lori Lowe; Carol Bradford; James Geiger; Jennifer Schwartz; Timothy M Johnson
Journal:  Cancer       Date:  2009-02-01       Impact factor: 6.860

Review 6.  Atypical Spitz tumours and sentinel lymph node biopsy: a systematic review.

Authors:  Aimilios Lallas; Athanassios Kyrgidis; Gerardo Ferrara; Harald Kittler; Zoe Apalla; Fabio Castagnetti; Caterina Longo; Elvira Moscarella; Simonetta Piana; Iris Zalaudek; Giuseppe Argenziano
Journal:  Lancet Oncol       Date:  2014-04       Impact factor: 41.316

7.  NanoStriDE: normalization and differential expression analysis of NanoString nCounter data.

Authors:  Christopher D Brumbaugh; Hyunsung J Kim; Mario Giovacchini; Nader Pourmand
Journal:  BMC Bioinformatics       Date:  2011-12-16       Impact factor: 3.169

8.  MicroRNA-34b/c suppresses uveal melanoma cell proliferation and migration through multiple targets.

Authors:  Feng Dong; Dinghua Lou
Journal:  Mol Vis       Date:  2012-03-01       Impact factor: 2.367

9.  miRTarBase update 2014: an information resource for experimentally validated miRNA-target interactions.

Authors:  Sheng-Da Hsu; Yu-Ting Tseng; Sirjana Shrestha; Yu-Ling Lin; Anas Khaleel; Chih-Hung Chou; Chao-Fang Chu; Hsi-Yuan Huang; Ching-Min Lin; Shu-Yi Ho; Ting-Yan Jian; Feng-Mao Lin; Tzu-Hao Chang; Shun-Long Weng; Kuang-Wen Liao; I-En Liao; Chun-Chi Liu; Hsien-Da Huang
Journal:  Nucleic Acids Res       Date:  2013-12-04       Impact factor: 16.971

Review 10.  MicroRNAs: Clinical Relevance in Colorectal Cancer.

Authors:  Joe Thomas; Masahisa Ohtsuka; Martin Pichler; Hui Ling
Journal:  Int J Mol Sci       Date:  2015-11-25       Impact factor: 5.923

View more
  7 in total

Review 1.  MicroRNA heterogeneity in melanoma progression.

Authors:  Anita Thyagarajan; Kenneth Y Tsai; Ravi P Sahu
Journal:  Semin Cancer Biol       Date:  2019-06-01       Impact factor: 15.707

2.  Expression patterns and bioinformatic analysis of miR-1260a and miR-1274a in Prostate Cancer Tunisian patients.

Authors:  Rahma Said; Yoelsis Garcia-Mayea; Nesrine Trabelsi; Nouha Setti Boubaker; Cristina Mir; Ahlem Blel; Nidhal Ati; Rosanna Paciucci; Javier Hernández-Losa; Soumaya Rammeh; Amine Derouiche; Mohamed Chebil; Matilde E LLeonart; Slah Ouerhani
Journal:  Mol Biol Rep       Date:  2018-09-24       Impact factor: 2.316

3.  HNRNPA2/B1 is upregulated in endocrine-resistant LCC9 breast cancer cells and alters the miRNA transcriptome when overexpressed in MCF-7 cells.

Authors:  Carolyn M Klinge; Kellianne M Piell; Christine Schaner Tooley; Eric C Rouchka
Journal:  Sci Rep       Date:  2019-07-01       Impact factor: 4.379

4.  High expression level of miR-1260 family in the peripheral blood of patients with ovarian carcinoma.

Authors:  Arash Adamnejad Ghafour; Demet Akdeniz Odemis; Seref Bugra Tuncer; Busra Kurt; Mukaddes Avsar Saral; Seda Kilic Erciyas; Ozge Sukruoglu Erdogan; Betul Celik; Pinar Saip; Hulya Yazici
Journal:  J Ovarian Res       Date:  2021-10-10       Impact factor: 4.234

5.  miR-21-5p promotes cell proliferation and G1/S transition in melanoma by targeting CDKN2C.

Authors:  Zhaohui Yang; Bo Liao; Xiaoyan Xiang; Sha Ke
Journal:  FEBS Open Bio       Date:  2020-03-24       Impact factor: 2.693

6.  MCPIP1 ribonuclease can bind and cleave AURKA mRNA in MYCN-amplified neuroblastoma cells.

Authors:  Iwona Nowak; Elżbieta Boratyn; Sebastian Student; Stephan F Bernhart; Jörg Fallmann; Małgorzata Durbas; Peter F Stadler; Hanna Rokita
Journal:  RNA Biol       Date:  2020-08-20       Impact factor: 4.652

7.  Glutaminase isoforms expression switches microRNA levels and oxidative status in glioblastoma cells.

Authors:  Juan de Los Santos-Jiménez; José A Campos-Sandoval; Clara Márquez-Torres; Nieves Urbano-Polo; David Brøndegaard; Mercedes Martín-Rufián; Carolina Lobo; Ana Peñalver; María C Gómez-García; Janet Martín-Campos; Carolina Cardona; Laura Castilla; Felipe da Costa Souza; Tzuling Cheng; Juan A Segura; Francisco J Alonso; Rui Curi; Alison Colquhoun; Ralph J DeBerardinis; Javier Márquez; José M Matés
Journal:  J Biomed Sci       Date:  2021-02-20       Impact factor: 8.410

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.